CSL SAYS IT DOES NOT ANTICIPATE ANY MATERIAL IMPACT DURING FISCAL YEAR 2027, ADDING THAT THE AGREEMENTS PROVIDE ADDITIONAL CERTAINTY REGARDING ITS EXPOSURE TO U.S.

DRUG PRICING AND CERTAIN SECTION 232 TARIFFS.

متن اصلی؛ ترجمهٔ فارسی ندارد